A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
- Registration Number
- NCT02928406
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1004
- Participants with histologically documented locally advanced (tumor [T] 4b, any node [N]; or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial carcinoma of the urinary tract
- Participants with measurable and/or non-measurable disease according to RECIST v1.1
- Participants must have progressed during or following treatment with at least one prior (and not more than 3) treatments for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
- If available, a representative formalin-fixed paraffin-embedded (FFPE) tumor specimen block should be submitted
- Eastern cooperative oncology group (ECOG) performance status 0, 1 or 2
-
Treatment with more than three prior lines of systemic therapy for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
-
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to study treatment initiation
- Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were not on active drug in that prior trial are eligible
- Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were in the follow-up phase of that prior trial and had stopped receiving active drug 4 or more weeks before study treatment initiation are eligible
-
Malignancies other than the one studied in this protocol within 5 years prior to Cycle 1, Day 1
-
Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol
-
Significant renal disorder indicating a need for renal transplant
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Atezolizumab Atezolizumab Participants will receive atezolizumab every 3 weeks (Q3W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
- Primary Outcome Measures
Name Time Method Percentage of Participants With Adverse Events (AEs) Baseline up to end of study (up to approximately 6 years) AEs were defined as any untoward medical occurrence in a subject administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. New disease, exacerbation of existing disease, recurrence of an intermittent medical condition not present at baseline, any deterioration in a laboratory value or other clinical test associated with symptoms or leading to a change in study/concomitant treatment or discontinuation from study drug as well as events related to protocol-mandated interventions are considered AEs.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Disease Control as Assessed by RECIST v1.1 Randomization up to disease progression or death from any cause, whichever occurred first (up to approximately 6 years) Disease control was determined separately on disease status using RECIST v1.1 by the investigator. Disease control rate was defined as the sum of the complete response, partial response, and stable disease rates.
Percentage of Participants With Best Overall Response (BOR) as Assessed by RECIST v1.1 Randomization up to disease progression or death from any cause, whichever occurred first (up to approximately 6 years) BOR was assessed by the investigators according to the RECIST v1.1. BOR was defined as a complete response (CR) or partial response (PR) determined on two consecutive investigator assessments \>= 4 weeks apart in participants with measurable disease at baseline. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 millimeters (mm); PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must have demonstrated an absolute increase of at least 5 mm. Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum on study.
Percentage of Participants With BOR as Assessed by Modified RECIST Randomization up to disease progression or death from any cause, whichever occurred first (up to approximately 6 years) BOR was assessed by the investigators according to the modified RECIST. BOR was defined as complete response (CR) or partial response (PR). CR includes complete disappearance of all tumor lesions and no new measurable or unmeasurable lesions confirmed by a consecutive assessment \>=4 weeks from the first documented date. PR is a decrease in the sum of the diameters of all target and all new measurable lesions \>=30%, relative to baseline, in the absence of CR confirmed by a consecutive assessment \>=4 weeks from the first documented date. The assessment of BOR included post-screening RECIST assessments obtained up to: 1) death from any cause, 2) last evaluable RECIST assessment in the absence of death, 3) start of a subsequent anti-cancer therapy, whichever occurred first.
Overall Survival (OS) Randomization until death from any cause (up to approximately 6 years) OS was defined as date of death (due to any cause) or censoring minus date of start of study treatment plus 1.
Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Randomization up to disease progression or death from any cause, whichever occurred first (up to approximately 6 years) PFS was defined as the date of first occurrence of tumor progression (earliest of the dates of the RECIST component indicating tumor progression) or date of death (in the absence of tumor progression) by any cause, whichever occurred first, or date of censoring minus date of start of study treatment plus 1.
PFS as Per Modified Response Evaluation Criteria in Solid Tumors (Modified RECIST) Randomization up to disease progression or death from any cause, whichever occurred first (up to approximately 6 years) PFS as per Modified RECIST was defined as:
* date of first occurrence of tumor progression after a modified confirmed response if the participant was a responder according to modified RECIST or
* date of first occurrence of tumor progression in case the participant was not a responder according to modified RECIST or
* date of death (in the absence of tumor progression) by any cause, or
* date of censoring whichever occurred first, minus date of start of study treatment plus 1Percentage of Participants With Disease Control as Assessed by Modified RECIST Randomization up to disease progression or death from any cause, whichever occurred first (up to approximately 6 years) Disease control was determined separately on disease status using modified RECIST by the investigator. Disease control rate was defined as the sum of the complete response, partial response, and stable disease rates.
Duration of Response (DOR) as Assessed by RECIST v1.1 Time from first occurrence of a documented response to disease progression or death from any cause, whichever occurred first (up to approximately 6 years) Duration of response was determined separately on disease status using RECIST v1.1 by the investigator. For overall responders, DoR was defined as the time from the date of first occurrence of a confirmed response (complete response or partial response) to date of tumor progression or death from any cause, or to censoring date: 1) end of response coincided with the date of tumor progression or death (in the absence of tumor progression) used for the PFS endpoint, 2) for a participant without disease progression or death following a response, the censored end of response coincided with the PFS censoring date (that was latest RECIST assessment or start of subsequent cancer therapy, whichever occurred first).
DOR as Assessed by Modified RECIST Time from first occurrence of a documented response to disease progression or death from any cause, whichever occurred first (up to approximately 6 years) Duration of response was determined separately on disease status using modified RECIST by the investigator. For overall responders, DoR was defined as the time from the date of first occurrence of a confirmed response (complete response or partial response) to date of tumor progression following that confirmed response or death from any cause, or to censoring date: 1) end of response was the date of tumor progression after that confirmed response or death (in the absence of tumor progression), 2) for a participant without disease progression or death following a response, the censored end of response was the latest RECIST assessment or start of subsequent cancer therapy, whichever occurred first.
Change From Baseline in Health-Related Quality of Life (HRQoL), as Assessed Using European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score Baseline, Day 1 of Cycles 1, 2, 3 and thereafter every 9 weeks for 54 weeks from study treatment start; and then every 12 weeks until progression/study discontinuation (up to approximately 6 years) (Cycle length = 21 days) The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale. Higher scores on the global health status and functional scales indicated better health status/function. Higher scores on the symptoms scales and symptom items indicated greater symptom burden.
Change From Baseline in European Quality of Life (EuroQoL) Group 5-Dimension 5-Level (EQ-5D-5L) Self Report Questionnaire Health Utility Score Baseline, Day 1 of Cycles 1, 2, 3 and thereafter every 9 weeks for 54 weeks from study treatment start; and then every 12 weeks until progression/study discontinuation (up to approximately 6 years) (Cycle length = 21 days) The EuroQol 5-Dimension Questionnaire (EQ-5D-5L) is a self-report health status questionnaire that consists of 6 questions used to calculate a health utility score for use in health economic analysis. There are two components to the EuroQol EQ-5D: 1) five health dimensions that assess mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; 2) a visual analogue scale (VAS) that measures health state. There are 5 response levels for each dimension (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems) with the highest level representing the worst outcome. The VAS is scored on a scale from 0 to 100, with 0 representing the worst imaginable health and 100 representing the best imaginable health.
Trial Locations
- Locations (175)
North Estonia Medical Centre Foundation; Oncology Center
🇪🇪Tallinn, Estonia
Hôpitaux Universit. de Genève Médecine Oncologie; Oncologie
🇨🇭Geneve, Switzerland
Luzerner Kantonsspital; Medizinische Onkologie
🇨🇭Luzern, Switzerland
Hospital Aleman
🇦🇷Caba, Argentina
Northern Cancer Institute
🇦🇺St Leonards, New South Wales, Australia
Cliniques Universitaires St-Luc
🇧🇪Bruxelles, Belgium
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium
UZ Brussel
🇧🇪Brussel, Belgium
Hospital de Cancer de Barretos
🇧🇷Barretos, SP, Brazil
Azienda Ospedaliera Universitaria Federico II
🇮🇹Napoli, Campania, Italy
Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik
🇩🇪München, Germany
CHU Sart-Tilman
🇧🇪Liège, Belgium
Medizinische Hochschule Hannover; Klinik für Urologie und Onkologische Urologie
🇩🇪Hannover, Germany
Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie
🇩🇪Halle (Saale), Germany
Hospital Alemao Oswaldo Cruz
🇧🇷Sao Paulo, SP, Brazil
Hospital Sao Lucas - PUCRS
🇧🇷Porto Alegre, RS, Brazil
Pronutrir - suporte nutricional e quimioterapia ltda.
🇧🇷Fortaleza, CE, Brazil
Universitätsklinikum Ulm; Klinik für Urologie
🇩🇪Ulm, Germany
Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Urologie
🇩🇪Göttingen, Germany
Alexandras General Hospital of Athens; Oncology Department
🇬🇷Athens, Greece
Universitätsklinikum "Carl Gustav Carus"; Klinik und Poliklinik für Urologie
🇩🇪Dresden, Germany
Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Urologie
🇩🇪Lübeck, Germany
Thermi Clinic; Oncology Clinic
🇬🇷Thermi Thessalonikis, Greece
IASO General Hospital of Athens
🇬🇷Athens, Greece
Metropolitan Hospital; 2Nd Oncology Clinic
🇬🇷Piraeus, Greece
Universitätsklinikum Tübingen; Klinik für Urologie
🇩🇪Tübingen, Germany
Max Super Speciality Hospital
🇮🇳New Delhi, Delhi, India
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház; Onkológiai Osztály
🇭🇺Szolnok, Hungary
Onkologische Schwerpunktpraxis
🇩🇪Heidelberg, Germany
Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus
🇩🇪Mönchengladbach, Germany
Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
🇭🇺Szeged, Hungary
Artemis Health Institute
🇮🇳Gurgaon, Haryana, India
AZ.Osp S. Orsola ? Malpighi-Reparto di Oncologia Medica
🇮🇹Bologna, Emilia-Romagna, Italy
Cork University Hospital
🇮🇪Cork, Ireland
ASST DI CREMONA; Dip. Medicina - S.C. Oncologia
🇮🇹Cremona, Lombardia, Italy
A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia
🇮🇹Udine, Friuli-Venezia Giulia, Italy
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
🇮🇹Meldola, Emilia-Romagna, Italy
Arcispedale Santa Maria Nuova; Oncologia
🇮🇹Reggio Emilia, Emilia-Romagna, Italy
Szpital Kliniczny Przemienienia Pa?skiego Uniwersytetu Medycznego im. Karola Marcinkowskiego
🇵🇱Poznan, Poland
Asst Papa Giovanni XXIII; Oncologia Medica
🇮🇹Bergamo, Lombardia, Italy
Maastricht University Medical Centre; Medical Oncology
🇳🇱Maastricht, Netherlands
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
🇮🇹Milano, Lombardia, Italy
Blokhin Cancer Research Center; Urological Dept
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
Hospital de Santa Maria; Servico de Oncologia Medica
🇵🇹Lisboa, Portugal
NZOZ Onko-Dent G. L. Slomian, Spolka Jawna
🇵🇱?ory, Poland
Hospital de Braga; Servico de Oncologia Medica X
🇵🇹Braga, Portugal
Azienda Ospedaliera S. Maria - Terni; Oncologia
🇮🇹Terni, Umbria, Italy
Ospedale Cannizzaro, Oncologia
🇮🇹Catania, Sicilia, Italy
Academ Ziekenhuis Groningen; Medical Oncology
🇳🇱Groningen, Netherlands
Azienda Ospedaliera di Verona-Policlinico G.B. Rossi; Oncologia Medica
🇮🇹Verona, Veneto, Italy
Hotel Dieu de France; Oncology
🇱🇧Beirut, Lebanon
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima
🇮🇹Padova, Veneto, Italy
NKI/AvL
🇳🇱Amsterdam, Netherlands
Szpital Grochowski im. dr med. Rafa?a Masztaka Sp. z o.o.
🇵🇱Warszawa, Poland
Narodny onkologicky ustav
🇸🇰Bratislava, Slovakia
Velindre Cancer Centre
🇬🇧Cardiff, United Kingdom
St. Antonius locatie Leidsche Rijn
🇳🇱Utrecht, Netherlands
Leicester Royal Infirmary NHS Trust
🇬🇧Leicester, United Kingdom
Centrul de Oncologie Sfantul Nectarie
🇷🇴Craiova, Romania
Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
🇪🇸Badalona, Barcelona, Spain
HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital San Pedro De Alcantara; Servicio de Oncologia
🇪🇸Caceres, Spain
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
🇪🇸Malaga, Spain
Hospital Clínico Universitario de Valencia; Servicio de Oncología
🇪🇸Valencia, Spain
Raigmore Hospital; Dept of Radiotherapy & Oncology
🇬🇧Inverness, United Kingdom
Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia
🇪🇸Girona, Spain
National Cheng Kung Uni Hospital; Dept of Hematology and Oncology
🇨🇳Tainan, Taiwan
Hospital La Fe
🇪🇸Valencia, Spain
Inselspital Bern; Universitätsklinik für Medizinische Onkologie, Klinische Forschungseinheit
🇨🇭Bern, Switzerland
Barts and the London NHS Trust.
🇬🇧London, United Kingdom
Herlev Hospital; Afdeling for Kræftbehandling
🇩🇰Herlev, Denmark
Rigshospitalet; Onkologisk Klinik
🇩🇰København Ø, Denmark
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico
🇮🇹Napoli, Campania, Italy
Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica
🇮🇹Bari, Puglia, Italy
Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia
🇮🇹Arezzo, Toscana, Italy
Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2
🇮🇹Pisa, Toscana, Italy
Royal Victoria Hospital
🇨🇦Barrie, Ontario, Canada
The Ottawa Hospital Cancer Center; General Campus
🇨🇦Ottawa, Ontario, Canada
Royal Marsden NHS Foundation Trust
🇬🇧Sutton, United Kingdom
Hospital Lucus Augusti; Servicio de Oncologia
🇪🇸Lugo, Spain
Hospital de Navarra; Servicio de Oncologia
🇪🇸Navarra, Spain
Complejo Hospitalario de Orense; Servicio de Oncologia
🇪🇸Orense, Spain
Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia
🇪🇸Murcia, Spain
Hospital Universitario Virgen del Rocio; Servicio de Oncologia
🇪🇸Sevilla, Spain
Hospital General Universitario de Valencia; Servicio de oncologia
🇪🇸Valencia, Spain
Macquarie University Hospital
🇦🇺Macquarie Park, New South Wales, Australia
Hospital Britanico de Buenos Aires
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Inst. Alexander Fleming; Oncologia
🇦🇷Buenos Aires, Argentina
Prince of Wales Hospital; Oncology
🇦🇺Randwick, New South Wales, Australia
Royal Hobart Hospital; Hematology/Oncology
🇦🇺Hobart, Tasmania, Australia
Austin Hospital Olivia Newton John Cancer Centre
🇦🇺Heidelberg, Victoria, Australia
Landeskrankenhaus Salzburg; Universitätsklinik für Urologie und Andrologie der PMU
🇦🇹Salzburg, Austria
Icon Cancer Foundation
🇦🇺South Brisbane, Queensland, Australia
Medizinische Universität Wien; Universitätsklinik für Urologie
🇦🇹Wien, Austria
Medizinische Universität Innsbruck; Universitätsklinik für Urologie
🇦🇹Innsbruck, Austria
Centro Integrado de Oncologia de Curitiba
🇧🇷Curitiba, PR, Brazil
University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD
🇧🇬Sofia, Bulgaria
Hospital Sírio-Libanês
🇧🇷Sao Paulo, SP, Brazil
Complex Oncology Center (COC)-Plovidiv
🇧🇬Plovdiv, Bulgaria
Tom Baker Cancer Centre-Calgary
🇨🇦Calgary, Alberta, Canada
Clinica del Country
🇨🇴Bogota, Colombia
Cross Cancer Institute ; Dept of Medical Oncology
🇨🇦Edmonton, Alberta, Canada
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
🇨🇳Nanjing City, China
Fakultni nemocnice u sv. Anny v Brne
🇨🇿Brno, Czechia
Fakultni nemocnice Kralovske Vinohrady
🇨🇿Praha, Czechia
Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni
🇨🇿Praha, Czechia
Aalborg Universitetshospital; Onkologisk Afdeling
🇩🇰Aalborg, Denmark
Aarhus Universitetshospital; Kræftafdelingen
🇩🇰Aarhus N, Denmark
Universitätsklinikum Erlangen; Medizinische Klinik 5 - Hämatound Internist Onko
🇩🇪Erlangen, Germany
Universitätsklinikum Münster, Klinik für Urologie und Kinderurologie
🇩🇪Münster, Germany
Orszagos Onkologiai Intezet
🇭🇺Budapest, Hungary
Semmelwies University of Medicine; Urology Dept.
🇭🇺Budapest, Hungary
A.O. Universitaria Policlinico Di Modena; Oncologia
🇮🇹Modena, Emilia-Romagna, Italy
Policlinico Universitario "Agostino Gemelli"; U.O.C. Oncologia Medica
🇮🇹Roma, Lazio, Italy
A.O. UNIVERSITARIA S. LUIGI GONZAGA; Oncologia Medica
🇮🇹Orbassano, Piemonte, Italy
Istituto Europeo Di Oncologia
🇮🇹Milano, Lombardia, Italy
IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia
🇮🇹San Giovanni Rotondo, Puglia, Italy
National Cancer Institute
🇱🇹Vilnius, Lithuania
A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia
🇮🇹Cagliari, Sardegna, Italy
Hospital of Lithuanian University of Health Sciences Kaunas Clinics - Endocrinology clinic
🇱🇹Kaunas, Lithuania
VU MEDISCH CENTRUM; Dept. of Medical Oncology
🇳🇱Amsterdam, Netherlands
HUC; Servico de Urologia e Transplantacao Renal
🇵🇹Coimbra, Portugal
Oncopremium Team Srl
🇷🇴Baia Mare, Romania
IPO do Porto; Servico de Oncologia Medica
🇵🇹Porto, Portugal
Hospital Univ. Central de Asturias; Servicio de Oncologia
🇪🇸Oviedo, Asturias, Spain
King Faisal Specialist Hospital & Research Centre; Oncology
🇸🇦Riyadh, Saudi Arabia
P.A. Herzen Oncological Inst. ; Oncology
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
Complejo Hospitalario de Althaia; Servicio de Oncologia
🇪🇸Manresa, Barcelona, Spain
Hospital del Mar Barcelona
🇪🇸Barcelona, Spain
Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
🇪🇸Sabadell, Barcelona, Spain
Hospital Univ Vall d'Hebron; Servicio de Oncologia
🇪🇸Sant Andreu de La Barca, Barcelona, Spain
Hospital Universitario Reina Sofia; Servicio de Oncologia
🇪🇸Córdoba, Cordoba, Spain
Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
🇪🇸Santiago de Compostela, LA Coruña, Spain
Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
🇪🇸Barcelona, Spain
Hospital Universitario de Canarias;servicio de Oncologia
🇪🇸La Laguna, Tenerife, Spain
Hospital Duran i Reynals; Oncologia
🇪🇸Barcelona, Spain
Hospital Clínic i Provincial; Servicio de Oncología
🇪🇸Barcelona, Spain
Hospital de Basurto; Servicio de Oncologia
🇪🇸Bilbao, Vizcaya, Spain
Hospital General Universitario de Guadalajara; Servicio de Oncologia
🇪🇸Guadalajara, Spain
Hospital Ramon y Cajal; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Clinico San Carlos; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario La Paz; Servicio de Oncologia
🇪🇸Madrid, Spain
Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia
🇪🇸Toledo, Spain
Kantonsspital Winterthur; Medizinische Onkologie
🇨🇭Winterthur, Switzerland
Chang Gung Medical Foundation-Linkou, Urinary Oncology
🇨🇳Taoyuan, Taiwan
Box Hill Hospital
🇦🇺Box Hill, Victoria, Australia
Calvary Mater Newcastle; Medical Oncology
🇦🇺Waratah, New South Wales, Australia
TATA Medical Centre; Medical Oncology
🇮🇳Kolkata, WEST Bengal, India
Ordensklinikum Linz Elisabethinen; Abteilung für Urologie und Andrologie
🇦🇹Linz, Austria
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
🇦🇹Wien, Austria
Clinical Hospital Centre Zagreb
🇭🇷Zagreb, Croatia
East Tallinn Central Hospital; Clinic of Internal Medicine
🇪🇪Tallinn, Estonia
Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept.
🇬🇷Kifisia, Greece
Euromedical General Clinic of Thessaloniki; Oncology Department
🇬🇷Thessaloniki, Greece
Papageorgiou General Hospital; Medical Oncology
🇬🇷Thessaloniki, Greece
Canberra Hospital; Medical Oncology
🇦🇺Canberra, Australian Capital Territory, Australia
Honvédelmi Minisztérium Állami Egészségügyi Központ; Onkológiai Osztály; Oncology department
🇭🇺Budapest, Hungary
HealthCare Global Cancer Centre; Medical Oncology
🇮🇳Ahmedabad, Gujarat, India
SHATOD - Sofia
🇧🇬Sofia, Bulgaria
Universitaetsspital Basel; Onkologie
🇨🇭Basel, Switzerland
Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca; Spital de zi-Parter
🇷🇴Cluj-Napoca, Romania
Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital; Oncology Day Unit
🇮🇪Dublin, Ireland
Policlinico Universitario Campus Biomedico Di Roma; U.O.Oncologia Medica
🇮🇹Roma, Lazio, Italy
Azienda Ospedaliera San Camillo Forlanini; Oncologia Medica
🇮🇹Roma, Lazio, Italy
Centrul de Radioterapie AMETHYST
🇷🇴Floresti, Romania
Oncomed SRL; Oncologie
🇷🇴Timisoara, Romania
Kantonsspital Graubünden Medizin Onkologie; Onkologie und Hämatologie
🇨🇭Chur, Switzerland
Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii
🇵🇱Lublin, Poland
Hospital Universitario Son Espases; Servicio de Oncologia
🇪🇸Palma De Mallorca, Islas Baleares, Spain
Policlinico Ospedaliero Ss Annunziata; U.O. Di Clinica Oncologica
🇮🇹Chieti, Abruzzo, Italy
Ospedale Regionale di Bellinzona Medizin Onkologie
🇨🇭Bellinzona, Switzerland
IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A
🇮🇹Genova, Liguria, Italy
Queen Elizabeth II Health Sciences Centre
🇨🇦Halifax, Nova Scotia, Canada